Form 4: HALO CEO Helen Torley Receives Performance Stock Units

Halozyme Therapeutics' President and CEO, Helen Torley, was granted 165,522 performance-based Restricted Stock Units tied to specific stock price targets over a four-year period.

Summary

• Helen Torley, President and CEO of Halozyme Therapeutics, Inc. (HALO), received a grant of 165,522 performance-based Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of HALO common stock.
• The RSUs are subject to performance-based vesting conditions over a four-year period.
• Vesting is tied to the average closing price of HALO common stock reaching specific price levels over 20 consecutive trading days.
• Up to 200% of the target RSUs can vest if price targets are met.
• Vesting occurs at price levels of $115, $130, $145, and $170, with 50% of the target vesting at each level.
• The reporting person must remain employed with Halozyme Therapeutics through the end of the performance period for the RSUs to vest.

Sentiment

Score: 7

Explanation: The grant of performance-based RSUs is generally positive as it aligns executive incentives with shareholder value creation and indicates management's confidence in future stock price appreciation. The specific, ambitious price targets suggest a strong internal outlook.

Positives

• The grant aligns the interests of the President and CEO directly with shareholder value creation through performance-based vesting tied to stock price appreciation.
• The potential for up to 200% vesting provides a strong incentive for management to drive significant stock price growth.
• The specified stock price targets ($115, $130, $145, $170) indicate management's confidence or aspirational goals for future share performance.

Negatives

• No direct negatives are presented in this filing, as it details a standard executive compensation grant.

Risks

• The performance-based Restricted Stock Units may not vest if the specified stock price targets are not met within the four-year performance period.
• The reporting person must remain employed with the company through the end of the performance period, introducing a retention risk.

Future Outlook

The grant of performance-based RSUs implies an optimistic outlook on the company's future stock price performance, with specific targets set at $115, $130, $145, and $170 over a four-year performance period. This indicates management's internal goals for significant shareholder value creation.

Management Comments

• Represents the grant of performance-based vesting Restricted Stock Units.
• Each Restricted Stock Unit represents a contingent right to receive one share of HALO common stock.
• Up to two hundred percent (200%) of the target Restricted Stock Units could vest if the average closing price of HALO common stock over a period of 20 consecutive trading days during a four-year performance period following the grant of the award equals or exceeds certain price levels specified in the award.
• Vesting is contingent on the Reporting Person remaining employed with the Registrant through the end of the performance period.

Industry Context

Performance-based equity awards, such as these RSUs, are a common and widely accepted practice in the biotechnology and pharmaceutical industries to incentivize executive leadership. They are designed to align executive compensation with long-term company performance and shareholder returns, particularly in sectors where innovation and market valuation are key drivers.

Comparison to Industry Standards

• This type of performance-based RSU grant, with tiered stock price targets and an employment condition, is a standard mechanism for executive incentive compensation across the biotech and broader S&P 500 companies.
• It directly links executive rewards to the achievement of specific, measurable stock price milestones, similar to programs seen at companies like Amgen, Gilead Sciences, or Regeneron, which often use stock performance metrics to drive long-term value.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact as executive compensation is directly tied to increasing shareholder value through stock price appreciation.
• Employees: No direct impact mentioned for general employees, but a successful stock performance could indirectly benefit employee morale and retention.
• Management: The President and CEO has a strong incentive to achieve the ambitious stock price targets, directly impacting their personal compensation.

Next Steps

• Halozyme Therapeutics' stock price performance will be monitored against the specified targets ($115, $130, $145, $170) over the four-year performance period.
• The President and CEO's continued employment with the company is required for the RSUs to vest.

Key Dates

Keywords

Halozyme Therapeutics, HALO, Helen Torley, Restricted Stock Units, RSU, Executive Compensation, Performance-based, Stock Grant, Insider Transaction, Corporate Governance